Alteogen Appoints Vivek Senoi as CBO

[Asia Economy Reporter Chunhee Lee] Alteogen announced on the 8th that it has recruited Dr. Vivek Senoi as the Chief Business Officer (CBO), the head of global business development, a position that had been vacant. The newly appointed CBO Senoi will be responsible for business development and licensing agreements by engaging with potential clients in the United States.

CBO Senoi has over 20 years of experience in business development and licensing agreements at companies such as AstraZeneca and Biocon. He played a pivotal role in the technology transfer of Biocon's oral insulin 'IN-105' to Bristol-Myers Squibb (BMS). Alteogen explained that they recruited him considering his extensive experience and capabilities, as well as his active participation in networks that play a central role in the global pharmaceutical industry.

An Alteogen official stated, “Due to the resignation of the previous CBO and restrictions on overseas travel caused by COVID-19, communication with companies we had been in contact with or new companies had been limited. Since the appointment of the new CBO Senoi, discussions related to contracts have gained momentum, and even in a short period, we are feeling the effects of his recruitment as the number of new companies showing interest in the 'ALT-B4' hyaluronidase platform is increasing.”

Alteogen also announced the recruitment of Vice President Kim Hang-yeon, a certified accountant, as the new Chief Financial Officer (CFO). The company explained that this move aims to revise internal accounting regulations in accordance with IFRS to enhance financial transparency and stability. Additionally, they added that they are reorganizing the IR team to strengthen communication with investors.

This content was produced with the assistance of AI translation services.